News
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa ...
By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...
Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...
Now, it’s worth noting Stock Advisor's total average return is 1,069% — a market-crushing outperformance compared to 184% for ...
Novo Nordisk faces challenges but offers growth potential through a weight loss pill and global expansion. Read more on why ...
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
Novo Nordisk (NYSE: NVO) is quite the divisive stock among both investors and analysts these days. Although its high-profile ...
20h
GlobalData on MSNFDA grants de novo authorisation to Artera’s prostate software
The US Food and Drug Administration (FDA) has granted de novo authorisation to Artera’s ArteraAI Prostate software. This ...
Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...
Novo Nordisk A/S (NYSE:NVO) is one of the best falling stocks to buy now. On August 7, HSBC maintained a “Hold” rating on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results